MILWAUKEE, Sept. 10, 2024 /PRNewswire/ -- Ademi LLP announces that a class action lawsuit has been filed on September 9, 2024 in the United States District Court for the Southern District of New York, captioned Mitchell v. Taro Pharmaceutical Industries Ltd., et al., Case No. 7:24-cv-06818, on behalf of a class of individuals and entities (the "Class") that held securities of Taro Pharmaceutical Industries Ltd. (NYSE: TARO), asserting claims under Sections 14(a) and 20(a) of the Securities Exchange Act of 1 ...

Combined entity is better positioned to compete in increasingly competitive generics industry Sun Pharma is the world's leading specialty generics company with a presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun Pharma's high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% ...

MUMBAI, India and NEW YORK, May 23, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as "Sun Pharma") and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today announced that the merger agreement between Taro and Sun Pharma was approved by the affirmative vote of Taro shareholders (including a vote of the majority of shares held by Taro shareholde ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 TARO PROVIDES RESULTS FOR YEAR ENDED MARCH 31, 2024 Hawthorne, NY, May 20, 2024 - Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and year ended March 31, 2024. Quarter ended March 31, 2024 Highlights ─ compare ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant's name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cove ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____ TARO PROVIDES RESULTS FOR THE QUARTER ENDED JUNE 30, 2023 Hawthorne, NY, July 26, 2023 - Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today p ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION ...

Financial Performance - Net sales for the quarter ended March 31, 2023, were $146.6 million, an increase of $3.3 million or 2.3% compared to the same quarter in 2022[7] - Gross profit for the year ended March 31, 2023, was $268.3 million, representing 46.8% of net sales, a decrease of $24.8 million from the previous year[7] - Operating income for the year was $17.7 million, down from $63.5 million, with a significant impact from prior year settlements and loss contingencies of $61.4 million[7] - Net income attributable to Taro for the year was $25.4 million, compared to $58.3 million in the previous year, resulting in earnings per share of $0.68 compared to $1.55[7] - Net income for the twelve months ended March 31, 2023, was $25,445 million, a decrease of 56.4% compared to $58,266 million in 2022[17] Expenses - Research and development (R&D) expenses for the year were $52.2 million, a decrease of $2.3 million compared to the prior year[7] - Selling, general and administrative (SG&A) expenses increased by $84.7 million to $198.4 million for the year ended March 31, 2023[7] - The company incurred $4,175 million in cash paid for income taxes during the year, down from $7,753 million in the previous year[17] Cash Flow and Liquidity - Cash flow provided by operations for the year was $31.8 million, a significant improvement from cash used in operations of $158.7 million in the prior year[7] - Cash flows from operating activities provided $31,750 million, a significant recovery from a cash outflow of $158,698 million in the previous year[17] - Cash and cash equivalents at the end of the period were $154,495 million, down from $251,134 million at the beginning of the period, reflecting a decrease of 38.5%[17] - As of March 31, 2023, total cash and cash equivalents, short-term bank deposits, and marketable securities amounted to $1.3 billion, consistent with the previous year[7] Investments and Assets - The company reported a net cash used in investing activities of $125,556 million, compared to $170,581 million in the prior year, indicating a reduction of 26.4%[17] - The company experienced a decrease in trade receivables, net, amounting to $37,482 million, compared to a decrease of $6,229 million in the previous year[17] - The company reported an increase in inventories, net, of $16,922 million, compared to an increase of $2,082 million in the previous year[17] - The company had a realized loss on the sale of long-lived assets of $136 million, down from $689 million in the previous year[17] - The company did not engage in any acquisitions during the year, contrasting with a cash outflow of $91,872 million for acquisitions in the previous year[17] - The company reported a decrease in cash received for income taxes to $14,156 million from $2,351 million in the previous year[17] Strategic Focus - The company anticipates continued focus on R&D and market expansion strategies in the upcoming fiscal year[10] - Taro's management emphasizes the importance of navigating regulatory challenges and market conditions to achieve future growth[10]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2022 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant's name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover ...